august im data drive stelara zytiga estim
higher similar last quarter underli pharma perform
ex-zytiga remicad key investor
sentiment indic expect
pharma perform ex-zytiga remicad key
repeatedli discuss pharma mix import absolut
perform given remicad eros upcom zytiga gener competit
key theme last quarter pharma grew exclud
zytiga number closer indic underli growth approxim
doubl sequenti remicad us declin stabl togeth
factor contribut upsid quarter commentari
healthcar confer reiter confid grow above-market
even face headwind upcom quarter trend around
pipelin tremfya erleada along indic expans current
drug stelara crohn key investor sentiment
sustain growth
modest chang overal model stelara zytiga move higher analysi
script drug price track lead us rais estim stelara
immunolog zytiga oncolog also lower
remicad estim reflect y/i declin vs declin
model prior given manag commentari mid-teen declin
stelara im data particular encourag given outsiz driver last
quarter crohn uptak investor question sustain
indic model pharma growth quarter exclud zytiga
reflect pt momentum deceler sequenti account
adjust net total pharma sale estim increas
bp corpor sale estim increas bp
remicad defens strategi hold share price remain focu im
track suggest remicad continu hold share comfort
estim us y/i declin primarili driven price
concess defens strategi remicad consist leverag
broader pharma portfolio contract discuss rebat make
remicad cost competit cheaper biosimilar
interchang biosimilar us see limit chang
import given remicad patient stabl
brand product limit visibl outcom septemb
lawsuit recent walgreen lawsuit alleg
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
anti-competit practic note manag commentari indic
competit valu price help stem biosimilar impact date
beyond acknowledg risk addit biosimilar entrant
potenti litig uncertainti estim alreadi reflect signific
conservat annual declin current anticip biosimilar
interchang near term
pipelin vs headlin risk offer glimps remicad eros
continu zytiga risk may come head earn call model
organ growth pharma exclud us zytiga
model declin us result gener competit
potenti month octob end stay harder
compar zytiga gener lead us forecast pharma growth
vs upsid come pipelin key upcom
guselkumab uptak last quarter uptak exist drug
indic expans darzalex multipl myeloma transplant inelig
patient stelara crohn diseas indic expans approv
xarelto cad/pad look next year esketamin addit
pipelin driver model revenu healthcar
confer gorski sound construct grow peer rate
compani suggest recent pharma call seem echo
view model pharma growth line forecast
brand market growth underli trend key us
evalu estim conserv appropri
rebalanc diversifi busi profil improv multipl remain
equal-weight state divers three-way street believ less
balanc portfolio weigh multipl sit discount
 versu histor level busi perceiv like
pharma compani analyst day recent leadership chang indic
increas sens urgenc consum md turnaround
near term pharma perform strateg commentari see wait
devic like rise drive perform note
tailwind includ pharma growth like slightli better major pharma
peer guidanc look achiev modestli conserv
potenti acceler consum think higher pharma exposur
warrant slightli greater discount histor level
maintain price target reflect ep whether
assum discount convers larg come futur
perform consum devic segment
 biosimilar balanc pipelin balanc sheet margin expans
balanc pipelin balanc sheet margin expans
price target base base case
ep assum trade mid-singl digit discount
given slight discount versu in-lin histor multipl
bull case ep
bull case ep
pharma pipelin exce expect due indic expans exist
franchis actelion surpass accret return target reinvest
pharma profit consum devic busi new commit return
addit sharehold buyback drive add ep
accret capit deploy drive upsid
base ep
base ep
revenu growth acceler remicad sale eros off-set
pipelin contribut improv devic consum actelion
acquisit integr time near term accret limit initi
 invest trade greater discount histor
bear ep
bear ep
revenu growth languish low singl digit amid deterior end
market remicad eros suffer aggress biosimilar price discount
addit entrant us market actelion integr fall track
md price pressur acceler multipl fall due structur
weaker revenu growth ineffici capit use long-term value-
pharma growth pipelin catalyst
off-set competit risk biosimilar
profil balanc improv segment
growth margin md consum
along margin expans initi
manag remain confid longer
term actelion accret growth
see potenti portfolio manag
expect divestitur ancillari slower
growth asset
pharma pipelin like take time
contribut near term risk
remicad biosimilar eros expect
margin initi remain track
increas bp year
manag also commit
reinvest upsid incom back
busi support growth
over-exposur pharma may weigh
 multipl histor in-lin
valuat
complet announc restructur
initi asset dispos
balanc sheet deploy
wacc return share repurchas
risk achiev price
anticip indic expans
exist pharma portfolio unabl off-set
investor concern around biosimilar
lower expect underli margin
expans benign price improv mix
wors expect fx headwind
greater expect price share
eros biosimilar across
exhibit sale ep
year year sale growth quarter date
quarter quarter sale growth quarter date
note us jv partnership cover ms
analyst david rising result pharmacycl acquisit book
us sale revenu profit share agreement place book net revenu
us imbruvica sale net residu profit earn sg reimburs
estim us imbruvica net revenu ou sale
imbruvica growth see increment benefit continu indic expans
effort said note acalabrutinib second-gener btk inhibitor
show better orr safeti cll patient ph studi may pose
longer term challeng compound current ph trial go
head head vs imbruvica core market high risk chronic lymphocyt leukemia
invokana daili type diabet treatment invokana first
inhibitor market follow astrazeneca farxiga recent boehringer/
lilli jardianc astrazeneca azn cover eu pharma team
cover ms analyst david rising note analysi group invokana
invokamet canagliflozin metformin farxiga xigduo dapagliflozin
market share perspect invokana continu see share loss
recent weekli data suggest share start
jardianc continu make inroad incumb
recent weekli read peg market share believ script track
indic jardianc cv benefit contribut share gain see cv
benefit class benefit benefit jardianc stand gain
rest plethora inhibitor market may also increas
potenti payer demand favor price use formulari
exclus pose anoth longer term threat note submit
snda invokana octob seek new indic reduc risk major
advers cardiovascular event mace base find canvas/canvs-r-
cv outcom fda set action date octob
estim us invokana sale ou sale
stelara continu add pharma franchis immunolog model us
stelara revenu expect growth acceler growth vs
last year given traction crohn uptak crohn diseas recent driver
key sustain recent trend
stelara face competit core psoriasi indic drug includ
novarti nv cosentyx inhibitor well valeant brodalumab anoth il-
molecul also acknowledg recent ii result boehring
ingelheim compound similar safeti profil better efficaci
stelara note ms pharma analyst david rising announc
global collabor bi mab plaqu psoriasi compound
ixekizumab call taltz report higher respons rate vs stelara patient
moder sever plaqu psoriasi said note dermatologist tend
conserv stelara long safeti track record remain competit advantag
addit see effort indic expans stelara extend life-cycle
drug lupu adolesc moder sever plaqu psoriasi ulcer
xarelto continu leader anti-coagul market see eliqui
continu make gain said indic expans cad/pad
compass like contribut xarelto gain current model
us xarelto sale
im data week roll basi suggest xarelto held share sinc
june note compass data set show signific prevent major
advers cardiac event patient coronari arteri diseas peripher arteri
diseas eliqui continu gain ground move xarelto share script
versu begin year
normal around share major zytiga share
increas last year current versu xtandi accord
latest weekli im data level last seen mid bit surpris share
shift perceiv xtandi advantag term requir co-
prescript steroid vs zytiga zytiga gener manufactur current face
month stay end nce exclus limit entri late octob
continu model gener competit current model us
ou revenu
